Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Treg Cell in the Treatment of GVHD
NCT06411184Phase 2Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 2, randomised, open-label trial of autologous regulatory T-lymphocytes in graft-versus-host disease (GVHD), sponsored by Xuzhou Medical University. Primary endpoint: Adverse events at 60 days. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
autologous regulatory T-lymphocytes
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06411184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411184.